Asset
CAVROTOLIMOD
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03086278 | phase1 | completed | 2017-10-20 | 2018-08-16 | Exicure, Inc. | A Study of AST-008 in Healthy Subjects |
| NCT03684785 | phase1_2 | terminated | 2018-12-13 | 2022-03-30 | Exicure, Inc. | Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.